Supplementary materials: The cost–effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark

dataset

posted on 2024-01-08, 19:00 authored by Lars H Ehlers, Mark Lamotte, Mafalda C Ramos, Susanne Sandgaard, Pia Holmgaard, Evan C Frary, Niels Ejskjaer

These are peer-reviewed supplementary material for the article ‘The cost–effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark’ published in the Journal of Comparative Effectiveness Research.

Table S1: Baseline Characteristics.
Table S2: Treatment Effects – First Line.
Table S3: Adverse Events.
Table S4: Treatment effects for second/third line treatments (treatment policy estimand).
Table S5: Proportion of patients on preventive medication.
Table S6: Screening and patient management proportions.
Table S7: Sensitivity and specificity of tests.
Table S8: Annual treatment costs applied (DKK, AIP 2020, [20]).
Table S9: Cost Inputs for the CDM (Costs inflated to 2020 values, DKK).
Table S10: Utilities used in CDM.
Table S11: Scenario analysis results.
Table S12: Breakdown of costs (DKK, per average patient).

Summary: Aim: To evaluate the cost–effectiveness of oral semaglutide+metformin versus empagliflozin+metformin in people with Type 2 diabetes uncontrolled on msetformin alone. Materials and methods: The IQVIA Core Diabetes Model was populated with efficacy data from a head-to-head study between oral semaglutide+metformin and empagliflozin+metformin. Danish costs and quality-of-life data were sourced from literature. Price per day was Danish Krone (DKK) 25.53 for oral semaglutide and DKK11.40 for empagliflozin. Discounting was fixed at 4%. Scenario and sensitivity analyses were performed. Results: Over a lifetime, Core Diabetes Model projected 8.78 and 8.75 quality-adjusted life-years and a total cost of DKK 447,633 and DKK 387,786, thereby generating an incremental cost–effectiveness ratio of DKK 1,930,548 for oral semaglutide+metformin versus empagliflozin+metformin. Scenario and sensitivity analyses showed the robustness of the outcomes. Duration of treatment with oral semaglutide is the key driver of the analyses. Conclusion: Oral semaglutide+metformin seems not cost effective versus empagliflozin+metformin in patients uncontrolled on metformin in Denmark.